Cathie Wood’s ARK Invest disclosed daily trades on Wednesday revealing a shift in its technology-focused portfolios, selling a significant position in Alphabet Inc. and redirecting capital toward Meta Platforms Inc. and gene-editing firm Beam Therapeutics Inc.
Across its ARKK Innovation ETF and ARKW Internet & Software ETF, the firm sold 84,392 shares of Alphabet, valued at approximately $28.55 million, according to filings. The moves reduce ARK’s exposure to the search and cloud computing giant as it rebalances among large-cap tech names.
In contrast, ARK acquired 43,091 shares of Meta Platforms, totaling $26.44 million, spread across the same two ETFs. The purchases signal continued conviction in the social-media and advertising platform as a core holding within its innovation thesis.
The fund manager also increased its position in Cambridge, Mass.-based Beam Therapeutics, buying 271,159 shares for $7.28 million. The transaction was split between ARKK and ARKG, the latter focused on genomics innovations. Separately, ARK added 47,113 shares of CRISPR Therapeutics AG for $2.58 million and purchased 204,206 shares of Intellia Therapeutics Inc. for $2.60 million, both within ARKK.
ARK trimmed its stake in Tempus AI Inc., reducing holdings by 22,767 shares for approximately $1.46 million through ARKK alone, marking a partial exit from the precision-medicine data company.
The trading activity comes amid broader market attention on Wood’s active portfolio strategy, which has drawn scrutiny over recent performance relative to passive index benchmarks. ARK has promoted select past performers through its ProPicks AI program, citing gains such as Super Micro Computer Inc. (+185%) and AppLovin Corp. (+157%), though those returns reflect historical rather than current positioning.
